Abstract
A recent study published in Nature Medicine reports that low-dose treatment with RGD-mimetic integrin inhibitors may paradoxically enhance angiogenesis and tumor growth. This work implies that delivery of these agents should be redesigned in order to avoid nanomolar plasma concentrations and to improve their efficacy to treat human cancers.
MeSH terms
-
Animals
-
Benzocycloheptenes / pharmacology*
-
Cell Proliferation / drug effects
-
Dose-Response Relationship, Drug
-
Humans
-
Integrins / antagonists & inhibitors*
-
Neoplasm Invasiveness
-
Neoplasms / blood
-
Neoplasms / blood supply
-
Neoplasms / drug therapy*
-
Neoplasms / pathology
-
Neovascularization, Pathologic / drug therapy*
-
Neovascularization, Pathologic / pathology
-
Peptides, Cyclic / pharmacology*
-
Signal Transduction / drug effects
-
gamma-Aminobutyric Acid / analogs & derivatives*
-
gamma-Aminobutyric Acid / pharmacology
Substances
-
5-(7-((4-(pyridin-2-ylamino)butyrylamino)methyl)-6,9-dihydro-5H-benzocyclohepten-5-yl)acetic acid
-
Benzocycloheptenes
-
Integrins
-
Peptides, Cyclic
-
cyclic arginine-glycine-aspartic acid peptide
-
gamma-Aminobutyric Acid